Platinum (iv)-fatty acid conjugates overcome inherently and acquired cisplatin resistant cancer cell lines: an in-vitro study

HIGHLIGHTS

• who: Einav Ratzon from the Cisplatin, Carboplatin and Oxaliplatin were purchased from SigmaStock solutions were, mM in phosphatebuffered saline (PBS) and dilution were made with PBS to reach the appropriate concentrations in the different assays. RJYs were synthesized at the laboratory of Anticancer Drugs Research Lab, Faculty of Pharmacy, Al-Quds University, Jerusalem, Abu-Dies, Palestine and dissolve in dimethyl sulfoxide (DMSO) (25, mM) and diluted to obtain final DMSO solutions of, .1-0., % in the different assays. Synthesized Platinum (IV) prodrugs were subjected to proton nuclear magnetic resonance (, NMR) and , Pt-NMR spectroscopy using Varian Unity . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.